NCT01575860View on ClinicalTrials.gov

Maintenance Lenalidomide in Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

May 30, 2018

Study Completion Date

October 31, 2022

Conditions
Lymphoma
Interventions
DRUG

Lenalidomide

Lenalidomide, 10mg, oral tablets, daily

Trial Locations (1)

19104

Jakub Svoboda, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01575860 - Maintenance Lenalidomide in Lymphoma | Biotech Hunter | Biotech Hunter